TrialCompass™ TCL
Back to trials
Phase 1RecruitingPriority 4 · Lower priorityNCT06393738

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ClinicalTrials.gov

Plain-language summary

This trial is testing ARV-393 for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

ARV-393 (DRUG): Oral daily dose of ARV-393 at a specified dose level | Glofitamab (DRUG): Glofitamab infusion per labelled prescribing information

  • ARV-393, Glofitamab

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is AITL?

Plain-language overview of AITL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing ARV-393 for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

ARV-393 (DRUG): Oral daily dose of ARV-393 at a specified dose level | Glofitamab (DRUG): Glofitamab infusion per labelled prescribing information

Drugs / treatments: ARV-393, Glofitamab

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 255 patients

Primary endpoint: Incidence of Dose Limiting Toxicities During First 28 Days; Percentage of Participants With Adverse Events Characterized by Severity, Seriousness, and Relationship to Study Drug as a Measure of Safety and Tolerability; Number of Participants With Abnormal Vital Signs, Abnormal ECG Readings (QT Interval) and Abnormal Laboratory Parameters; Percentage of Participants With Grade 3 or Grade 4 Clinical Lab Abnormalities Using the Common Terminology Criteria for Adverse Events (CTCAE) With Scale From Grade 1 Grade 5. Higher Score Means Worse Outcome

Ages: 18 Years to —

Start date: 2024-09-05 | Est. completion: 2028-03

Locations

8 US sites · 17 total

Connecticut, Michigan, New Jersey, New York, Ohio, Tennessee, Texas

Contact

Arvinas Operations, Inc. | clinicaltrialsARV-393@arvinas.com | 475-345-0791

Sponsor: Arvinas Inc. (INDUSTRY)

Tags

AITL/TFH · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06393738

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.